Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

NCT01487785 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: LDE225+gemcitabine

Sponsor

Novartis Pharmaceuticals